MedTrace Logo

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

NCT03128021 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

The Department of Psychiatry at the University of Pittsburgh is conducting a research study to learn about the changes that occur in the brain when individuals suffer from and then are treated for depression. The NEMO study has two main purposes. The first is to provide medication treatment to individuals ages 60 and older who are currently depressed.

The second part of the study involves completing a series of 4 MRIs, which assess changes in brain function over the course of treatment. This research may help investigators to develop faster and more effective treatment plans in the future, as brain responses that are detected early in treatment may predict how well an individual will respond to antidepressant medication.

Conditions

Interventions

DRUG

Escitalopram Pill

Double-blinded, randomly assigned

OTHER

Placebo

Double-blinded, randomly assigned

DRUG

Levomilnacipran Pill

Double-blinded, randomly assigned

Sponsors & Collaborators

  • Weill Cornell Institute of Geriatric Psychiatry

    collaborator UNKNOWN

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Howard Aizenstein

    lead OTHER

Principal Investigators

  • Howard J Aizenstein, MD, Ph.D. · Charles F. Reynolds III and Ellen G. Detlefsen Endowed Chair in Geriatric Psychiatry and Associate Professor of Bioengineering and Clinical and Translational Science

  • Carmen Andreescu, MD · Assistant Professor of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2023-06-21
Completion
2023-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03128021 on ClinicalTrials.gov